Policy & Price

The Business of Saving Lives


‘We don’t apologize for being highly profitable until our patents run out,” says the man seated in the barest office of any corporate leader I’ve visited. Read more here.

Orphan drug spending not as high as originally thought, study says

Orphan drug spending not as high as originally thought, study says

Total orphan drug spending represented approximately 1 percent of total U.S. health care spending, according to the authors. Rising concerns about spending on prescription drugs that treat rare diseases are not justified, according to a new analysis in the journal Health Affairs. “We wanted to focus on the true impact of orphan drugs,” said Victoria […]

Are You Just a Number? How New Healthcare Value Frameworks Miss the Point


By Tomas J. Philipson and Jason Shafrin New value frameworks in health care have emerged due to increasing cost pressures. Although value frameworks can be useful tools, they should be used to complement the patient-physician treatment decision-making process, rather than substitute for it. This entails getting away from “one size fits all” rules as well […]

Drugmakers’ Pricing Power Remains Strong


Price increases continue despite pushback from insurers, U.S. lawmakers By JOSEPH WALKER | July 14, 2016 5:30 a.m. Pharmaceutical companies’ power to raise prices is firmly intact despite pushback from health insurers, scrutiny by U.S. lawmakers and anxiety about rising prescription drug spending. More than two-thirds of the 20 largest​pharmaceutical companies said price increases boosted sales of […]

EP Vantage Shifting CAR-Ts Into a Higher Gear


Chimeric antigen receptor T cell (CAR-T) therapy has indisputably become one of the industry’s hottest topics and the next 18 months could see the first CAR-T drugs filed for US approval. But behind the excitement for all things CAR-T lie a number of obstacles in their path to approval. In its second deep-dive into the […]

Drug-Pricing Debate: Looking Past Big Pharma’s Nightmare Scenario


Government action might not be needed to pressure prices on some drugs   A comprehensive government crackdown on high drug prices isn’t likely soon. Still, investors shouldn’t let their guard down. Biotech and pharmaceutical stocks have struggled since last summer when the controversy erupted into a big political issue. Last week’s congressional hearing on the […]

UBS, MPM team up on $471 million cancer fund to speed drug development


A $471 million UBS venture fund aims to generate annual returns “north of 10 percent” for its European and Asian investors by financing new cancer drugs, helping speed them from the lab to the point where drug companies buy their rights. Mark Haefele, global chief investment officer at the Swiss bank’s wealth management unit, said […]

FDA Nominee Not All Good News for Drug Makers


An industry-friendly commissioner seems to be coming to the Food and Drug Administration. While he is favored by many executives, not all drug makers will be happy once he gets on the job. Read more here.

The Biotech Stock Safety Net


Call it the Pfizer put. The giant pharmaceutical company sold €4 billion ($4.22 billion) in bonds this week, paying a yield of almost nothing.The ease and low cost of Pfizer’s borrowing shows that it or any of its major rivals could easily fund the acquisition of almost any biotech. Read more here.